<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501863</url>
  </required_header>
  <id_info>
    <org_study_id>AN1</org_study_id>
    <nct_id>NCT02501863</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty</brief_title>
  <official_title>Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Center, Seoul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Medical Center, Seoul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The postoperative analgesic effect of the continuous 3-in-1 femoral nerve block (FNB) with
      ropivacaine/fentanyl or with ropivacaine were compared in total knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients of American Society of Anesthesiologist physical status Ⅰor Ⅱ undergoing total
      knee arthroplasty under spinal anesthesia would be enrolled and randomly divided into two
      groups (R, &quot;3-in-1&quot; using a 30 ml of ropivacaine 0.375% and a continuous 3-in-1 with a
      ropivacaine 0.2%(8mL/h) for 48 h after operation, RF: Fifty ug of fentanyl will be added to a
      bolus(30ml ropivacaine 0.375%) and 1ug/ml of fentanyl will be mixed to a continuous
      infusion(8mg/h, ropivacaine 0.2%). Spinal anesthesia will be done after the insertion of
      femoral catheter. IV PCA with hydromorphone(0.15mg/ml, 0-1-10), will be used for rescue
      analgesics. Visual analgesia scale, hydromorphone consumption, side effects until 48h after
      operation and satisfaction will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain on the VAS(Visual Analog Scale)</measure>
    <time_frame>During 48 hour after operation</time_frame>
    <description>VAS(resting, movement) at operation day, postoperation 1 day, postoperation 2 day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participant with side effects</measure>
    <time_frame>During 48 hour after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ropivacaine+fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Femoral nerve block with ropivacaine+fentanyl
Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Femoral nerve block with ropivacaine
Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femoral nerve block with ropivacaine+fentanyl</intervention_name>
    <description>Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone</description>
    <arm_group_label>Ropivacaine+fentanyl</arm_group_label>
    <other_name>RF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femoral nerve block with ropivacaine</intervention_name>
    <description>Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA PS 1 to 3 undergoing total knee arthroplasty under spinal anesthesia

        Exclusion Criteria:

          -  Patients were excluded from this study if they had contraindications to a regional
             anesthetic technique (e. g., local infection, sepsis, coagulation abnormality),
             allergy to local anesthetic or fentanyl, preexisting neurologic deficit in the lower
             extremities, and inability to comprehend the pain scales or use IV patient-controlled
             analgesia (PCA) device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mijung Yun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Medical Center</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Medical Center, Seoul</investigator_affiliation>
    <investigator_full_name>Mija Yun, MD, PhD</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

